Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
2023-503289-22-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing LY3541860 with Placebo (2 arms). Primary endpoint: Cumulative number of new T1 gadolinium-enhancing brain lesions. Started Jul 2024; status: completed.
02
Drugs
LY3541860
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-503289-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503289-22-00.